Literature DB >> 1312263

Steady-state pharmacokinetics of rufloxacin in elderly patients with lower respiratory tract infections.

R Cogo1, R Rimoldi, R Mattina, B P Imbimbo.   

Abstract

The pharmacokinetics of rufloxacin, after repeated doses, was evaluated in 12 elderly patients with lower respiratory tract infections. Patients were given a single loading dose of 400 mg on the first day of treatment and single daily maintenance doses of 200 mg for the next 6-9 days. Serum concentrations of the drug were determined by high-performance liquid chromatography (HPLC) at regular intervals during treatment and fitted to a one-compartment open model for repeated doses. The maximum serum concentration after the first dose was 6.46 +/- 1.06 (mean +/- SEM) micrograms/ml and was reached in 4.3 +/- 0.8 h after the first administration. The elimination half-life was 28.7 +/- 4.1 h. The area under the serum levels-time curve from 0 to 24 h was 103 +/- 14 micrograms/h/ml after the first dose. On the last day of observation it increased to 155 +/- 28 micrograms/h/ml, with a mean extent of accumulation of 2.3 +/- 0.3 times. The elimination half-life was comparable to those in other studies in healthy young subjects, while plasma levels were about 80% higher. These results suggest that in elderly patients elevated drug concentrations may be reached in the serum. Although no untoward reactions related either to the drug concentration in serum or the dose have been noted with rufloxacin, this patient population should nevertheless be monitored carefully for adverse effects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1312263     DOI: 10.1097/00007691-199202000-00006

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  8 in total

1.  Penetration of rufloxacin into the cerebrospinal fluid in patients with inflamed and uninflamed meninges.

Authors:  M V Moretti; S Pauluzzi; M Cesana
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

Review 2.  Rate and extent of drug accumulation after multiple dosing revisited.

Authors:  Dion R Brocks; Reza Mehvar
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

3.  Absence of effect of rufloxacin on theophylline pharmacokinetics in steady state.

Authors:  M Kinzig-Schippers; U Fuhr; M Cesana; C Müller; A H Staib; S Rietbrock; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

4.  Biliary excretion of rufloxacin in humans.

Authors:  G Privitera; G Nicastro; B P Imbimbo; M Cesana; M Visconti; F Lombardi; G Tagliabue; E Faleschini; F Colturani; P Franzini
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

5.  Comparative activity of the new fluoroquinolone rufloxacin (MF 934) against clinical isolates of gram-negative and gram-positive bacteria.

Authors:  S M Qadri; Y Ueno; G Postle; D Tullo; J San Pedro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

6.  Effects of magnesium-aluminum hydroxide antacid on absorption of rufloxacin.

Authors:  M Lazzaroni; B P Imbimbo; S Bargiggia; O Sangaletti; L Dal Bo; G Broccali; G Bianchi Porro
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

7.  Pharmacokinetics of rufloxacin in patients with impaired renal function.

Authors:  G Perry; T G Mant; P J Morrison; S Sacks; J Woodcook; R Wise; B P Imbimbo
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

8.  Double-blind, comparative study of rufloxacin once daily versus amoxicillin three times a day in treatment of outpatients with exacerbations of chronic bronchitis.

Authors:  W Klietmann; M Cesana; R K Rondel; J Focht
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.